UBS Group’s AIM ImmunoTech AIM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.22K | Buy |
28,931
+28,930
| +2,893,000% | +$13.2K | ﹤0.01% | 8697 |
|
|
2026
Q1 | $1 | Sell |
1
-378
| -100% | -$383 | ﹤0.01% | 10399 |
|
|
2025
Q4 | $428 | Buy |
379
+75
| +25% | +$139 | ﹤0.01% | 9971 |
|
|
2025
Q3 | $833 | Sell |
304
-878
| -74% | -$3.93K | ﹤0.01% | 9529 |
|
|
2025
Q2 | $10.2K | Buy |
1,182
+1,104
| +1,415% | +$10.9K | ﹤0.01% | 8851 |
|
|
2025
Q1 | $951 | Buy |
+78
| New | +$1.25K | ﹤0.01% | 9608 |
|
|
2024
Q4 | – | Hold |
0
| – | – | – | 9844 |
|
|
2024
Q3 | – | Sell |
-213
| Closed | -$7.1K | – | 9385 |
|
|
2024
Q2 | $7.95K | Buy |
+213
| New | +$9.04K | ﹤0.01% | 7824 |
|
|
2024
Q1 | – | Sell |
-129
| Closed | -$5.35K | – | 9108 |
|
|
2023
Q4 | $5.66K | Sell |
129
-36
| -22% | -$1.68K | ﹤0.01% | 7771 |
|
|
2023
Q3 | $7.51K | Buy |
+165
| New | +$10.2K | ﹤0.01% | 7226 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 8746 |
|
|
2023
Q1 | – | Sell |
-293
| Closed | -$15.2K | – | 9489 |
|
|
2022
Q4 | $9.07K | Buy |
293
+232
| +380% | +$10.8K | ﹤0.01% | 8695 |
|
|
2022
Q3 | $4K | Buy |
61
+8
| +15% | +$560 | ﹤0.01% | 9505 |
|
|
2022
Q2 | $4K | Buy |
+53
| New | +$5.09K | ﹤0.01% | 9265 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 11668 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 11479 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 10865 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 10458 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 9997 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 9236 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 8885 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 8813 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 8948 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 8852 |
|
|
2019
Q3 | – | Sell |
-9
| Closed | -$2.18K | – | 8655 |
|
|
2019
Q2 | $4K | Sell |
9
-28
| -76% | -$16.9K | ﹤0.01% | 7509 |
|
|
2019
Q1 | $26K | Buy |
37
+25
| +208% | +$22.3K | ﹤0.01% | 6096 |
|
|
2018
Q4 | $9K | Buy |
12
+4
| +50% | +$3.67K | ﹤0.01% | 7327 |
|
|
2018
Q3 | $7K | Buy |
8
+3
| +60% | +$3.66K | ﹤0.01% | 7387 |
|
|
2018
Q2 | $7K | Buy |
+5
| New | +$7.32K | ﹤0.01% | 7383 |
|
|
2018
Q1 | – | Sell |
-1
| Closed | -$2.09K | – | 7753 |
|
|
2017
Q4 | $3K | Buy |
+1
| New | +$1.44K | ﹤0.01% | 7589 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | -$1.75K | – | 7672 |
|
|
2017
Q2 | $1K | Sell |
1
-1
| -50% | -$2.47K | ﹤0.01% | 7605 |
|
|
2017
Q1 | $5K | Hold |
2
| – | – | ﹤0.01% | 7046 |
|
|
2016
Q4 | $7K | Buy |
2
+1
| +100% | +$4.03K | ﹤0.01% | 7142 |
|
|
2016
Q3 | $4K | Hold |
1
| – | – | ﹤0.01% | 7262 |
|
|
2016
Q2 | $5K | Sell |
1
-1
| -50% | -$6.56K | ﹤0.01% | 7200 |
|
|
2016
Q1 | $14K | Hold |
2
| – | – | ﹤0.01% | 6484 |
|
|
2015
Q4 | $9K | Hold |
2
| – | – | ﹤0.01% | 7413 |
|
|
2015
Q3 | $19K | Hold |
2
| – | – | ﹤0.01% | 6788 |
|
|
2015
Q2 | $26K | Buy |
+2
| New | +$24.8K | ﹤0.01% | 6651 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 8191 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 9081 |
|
Other funds holding AIM
VF
GSC
TRCT
CA
UBS Group's AIM Position: Q2 2026 in Review
UBS Group increased its AIM ImmunoTech (AIM) stake by 2,893,000% in Q2 2026, buying an estimated $13.2K and bringing the position to 28,931 shares worth $8.22K. The position accounts for ﹤0.01% of the portfolio, ranked #8697.
UBS Group first reported a position in AIM in Q2 2015 and has held it in 27 quarters since. The position peaked at $26K in Q1 2019. 18 funds tracked by Wall St. Rank hold AIM as of Q2 2026.
- UBS Group held 28,931 shares of AIM ImmunoTech worth $8.22K as of Q2 2026.
- UBS Group bought 28,930 AIM ImmunoTech shares in Q2 2026, an estimated $13.2K.
- AIM ImmunoTech made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8697 holding.
- UBS Group first reported a position in AIM ImmunoTech in Q2 2015 and has held it in 27 quarters since.
- UBS Group's AIM ImmunoTech position peaked at $26K in Q1 2019.
- 18 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.